“More than 100,000 Americans are hospitalized each year and between 15,000 and 20,000 Americans die each year from ulcers and gastrointestinal bleeding linked to NSAID use.”
A study conducted at the Spanish Centre for Pharmacoepidemiological Research revealed that the risk of gastrointestinal complications due to nonsteroidal anti-inflammatory drug (NSAID) use varies by specific NSAID administered and by dosage.
The study further determined that NSAIDs with a long half-life or slow-release formulation are associated with a greater risk of GI bleeding or perforation. Study findings are published in the June issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology. [See “Variability among NSAID drugs in risk of upper gastrointestinal bleeding.”]
How Lining of Stomach & Gut May Be Injured
NSAIDs such as Advil, Motrin and Aleve are drugs that treat pain and inflammation by blocking the action of two cyclooxygenase (COX) enzymes.
• COX-2 promotes inflammation,
• But COX-1 protects the lining of the stomach.
• If an NSAID inhibits both COX-1 and COX-2, GI bleeding and ulcers can result.
According to the American College of Gastroenterology, it has long been recognized that persons using NSAIDs are at a significantly increased risk of gastrointestinal complications – for instance, injury to the intestinal lining that can result in ulcers and/or gastrointestinal bleeding.
100,000 Will Be Hospitalized, 15-20,000 Die This Year in US
With millions taking NSAID pain medications every day, it is estimated that more than 100,000 Americans are hospitalized each year and between 15,000 and 20,000 Americans die each year from ulcers and gastrointestinal bleeding linked to NSAID use.
To reduce the morbidity associated with NSAIDs, specific estimates for individual drugs and individual groups of patients with different risk profiles are needed. This study assessed the risk of upper GI bleeding and perforation among individual NSAIDs and analyzed the correlation between this risk and the degree of inhibition of whole blood COX-1 and COX-2 in vitro.
The research team conducted a systematic review of nine observational studies on NSAIDs and upper GI bleeding/perforation published between 2000 and 2008. The article criteria were: 1) report case–control or cohort studies evaluating traditional NSAID or coxib use and upper GI bleeding/perforation in the general population, and 2) provide either an estimate or enough data to estimate a relative risk comparing NSAID users with nonusers. The pooled relative risk (RR) estimates of upper GI bleeding/perforation for individual NSAIDs was calculated, as well as whether the degree of inhibition of whole blood COX-1 and COX-2 in vitro by average circulating concentrations predicted the RR of upper GI bleeding/perforation.
• The analysis suggests that NSAID-associated upper GI toxicity is the result of two pharmacologic features:
– Drug exposure [amount and length]
– And [whether the drug is] sparing of COX-1 activity.
• These findings support the notion that there are multifactorial determinants in the risk of upper GI bleeding/perforation among NSAID users, including:
– Clinical background,
– Use of concomitant medications,
– Or a possible genetic susceptibility.
Study leader Luis A. García Rodríguez, MD, states,
• “We showed that persistent exposure to the drug is an important independent determinant;
• “In fact, drugs with a long half-life or slow-release formulation were associated overall with a greater risk than NSAIDs with a short half-life.
• “We observed the lowest GI toxicity with coxibs – that is, celecoxib and rofecoxib,
• “Which supports the notion that sparing of COX-1 in the GI tract and possibly in platelets translates clinically to [less] upper GI risk.”
Detailed Results for Individual NSAIDS
[Note: According to the article, the average risks of upper GI bleeding/perforation for individual NSAIDs were as follows. To determine whether a branded product you use is included in one of these generic categories, start here. A relative risk (RR) of 1.0 would represent no added risk of bleeding. So the RR of 5.63 for naproxen, for example, means average risk is 463% greater than normal.
Risk estimates of more than 5 were as follows:
• 14.54 (95% CI 5.87-36.04) for ketorolac (Toradol, used for acute pain only),
• 9.94 (95% CI 5.99-16.50) for piroxicam,
• 5.63 (95% CI 3.83–8.28) for naproxen,
• 5.57 (95% CI 3.94–7.87) for ketoprofen, and
• 5.40 (95% CI 4.16–7.00) for indomethacin.
All of these “individual traditional NSAIDs were characterized by a profound and coincident inhibition (more than 80%) of both COX isozymes,” the authors note.
Other risk estimates include:
• 4.15 (95% CI 2.59-6.64) for meloxicam,
• 3.98 (95% CI 3.36-4.72) for diclofenac,
• 2.69 (95% CI 2.17-3.33) for ibuprofen,
• 2.12 (95% CI 1.59-2.84) for rofecoxib,
• 1.42 (95% CI 0.85-2.37) for celecoxib,
• And 1.44 (95% CI 0.65-3.2) for aceclofenac.]
Sources: Arthritis & Rheumatism (Wiley-Blackwell) news release, May 26, 2010; and cited article, “Variability among NSAID drugs in risk of upper gastrointestinal bleeding.”